December 18, 2020
Thawing antibodies - Freeze Thaw technology for handling mAbs on a higher quality level
Monoclonal antibodies: Improved quality and better results thanks to controlled freezing and thawing
In a field as sensitive as biopharmaceutical development and production, controlled processes and procedures have always played a vital role and will continue to do so. This is especially true for highly delicate substances such as monoclonal antibodies derived from white blood cells. They require particular care and sensitive handling throughout every step of the development and production- but also the logistics process in order not to be compromised in their efficacy. Additionally, speedy freezing and thawing rates can add to improved levels of quality and lead to better overall results.
Definition and history: What are monoclonal antibodies?
Monoclonal antibodies (mAb or moAb) are immunoglobulins (e. g. IgG) made by cloning a unique white blood cell, with all subsequent antibodies derived this way tracing back to the unique parent cell. They can also be engineered by increasing the therapeutic targets of one single monoclonal antibody to binding capacity towards two epitopes, resulting in so-called bispecific monoclonal antibodies. It is possible to produce monoclonal antibodies that bind to virtually any suitable antigen and antibody conjugates with fluorescence- or radioprobes, making them an important tool in fields like biochemistry, molecular biology, and medicine.
The history of medically used primary antibodies can be traced as far back as the late 19th century when they were originally used for tetanus and diphtheria therapies. Today, the application of moAb is much more versatile and they are not only being utilized for therapeutic but also for diagnostic purposes (e. g. ELISA assays). Their importance has increased significantly ever since they were first approved by the FDA in 1986.1
As opposed to polyclonal antibodies, monoclonal antibodies have the added benefit of being derived from the same lineage. This means their results can be reproduced endlessly by always resorting to aliquots of the same original batch. This last fact notwithstanding, production and the general handling of any kind of antibody are complex processes and require an environment that is both sterile and controllable. This applies to every single step along the production process, from development all the way to the final administration, and includes centrifugation, freeze-thaw cycles, multiple handling steps such as dilution to final concentration at room temperature, storage, shipping as well as thawing after long-term storage conditions. All these procedures are equally important in order to guarantee the best possible result for the patient.
The benefits of freezing/-thawing antibodies at a fast rate
With solutions and substances as delicate as blood cells and the antibodies derived thereof, the type of freezing process employed can have a major impact on their final quality, even if preservatives and cryoprotectants (e. g. sodium azide, glycerol) are added to antibody solutions contained in vials. The freezing speed affects both the frozen substance’s homogeneity and viscosity: With virtually any traditional freeze and thaw processes, parts of the substance will always show less activity based on the stress it is exposed to during freezing and thawing. An adequate freezing and thawing rate is thus a key parameter for achieving homogenous results without a major loss of active antibody concentration, hence quality.
Various tests have confirmed that a consistently high freezing velocity - which can be achieved with progressive single-use platforms - leads to a significantly lower level of Cryoconcentration (the protein concentration in the solid or liquid parts of a partially frozen mixture), denaturation and formation of aggregates. As a logical consequence, the original characteristics of the substance to be frozen will be better preserved when processed at a speedy and consistent freezing/thawing rate. We implement this with our laboratory freezer, pharma freezer and cryogenic freezer.
The risks of freezing/thawing antibodies at a slow rate
Slow freezing, on the other hand, is primarily characterized by differing freezing rates with a possibly adverse impact on the drug substance’s quality. A slower freezing process leads to the formation of longer ice crystals, which can negatively affect antibody storage. The formation of crystalline structures furthermore causes tension, which in turn can destroy up to 20 % of all contained proteins, without the presence of any protease enzymes! And as the cold temperatures penetrate the substance from the outside in, this can lead to an expansion of the core with the result of harming or destroying the surrounding material.
Furthermore, the slow freezing rates offered by static freezers lead to increased levels of Cryoconcentration. In the worst case scenario this can lead to the destruction of a high number of antibodies caused by friction and rupture. Highly concentrated substances such as mAb, however, require a homogeneous freezing process in order to maintain the original quality in the best way possible.
New opportunities and chances: Processing mAb with next-level technology
The implementation of single-use technology in the biopharmaceutical industry is growing rapidly, not least because of increased yields, the adaptability of disposable components and the acceptance of personalised therapies and medical compounds. On top of that, single-use platforms facilitate a rapid production of clinical trial material, monoclonal antibody reagents for western blotting, and cell as well as gene therapies.
Single-use technologies are highly flexible and scalable; thus, they offer the ideal solution for processing antibodies, cells and genes in a variety of volumes. Innovative approaches open up new formulation opportunities that would not be possible with traditional systems, tried-and-tested as they may be.
The growing range of therapies and compounds calls for plants and systems that are or can be adapted to the increased speed of development and production as well as constantly changing requirements. In the case of monoclonal antibodies special focus should be put on viscosity: As a result of protein-protein interactions, concentrated mAb solutions can exhibit high levels of viscosity that may pose challenges during the manufacturing process.
However, viscosity tests conducted by Single Use Support have shown that the degree of viscosity does not impact the filling process. Nonetheless, with RoSS.FILL, the speed and force of liquid throughput can be regulated and adjusted to the respective product conditions. This allows for individually controlled filling processes before the highly sensitive substances can be sent on to the freezing process - and all of this achieved with a single platform.
1.Jacquemart R, Vandersluis M, Zhao M, Sukhija K, Sidhu N, Stout J. A Single-use Strategy to Enable Manufacturing of Affordable Biologics. Computational and Structural Biotechnology Journal. Published online 2016:309-318. doi:10.1016/j.csbj.2016.06.007